Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Has Consensus Price Target of $100.86

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been assigned an average rating of “Moderate Buy” from the ten research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $104.57.

Several research analysts have issued reports on the company. Jefferies Financial Group increased their price objective on Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, October 15th. Guggenheim upped their price target on shares of Tarsus Pharmaceuticals from $89.00 to $97.00 and gave the stock a “buy” rating in a research note on Thursday. Zacks Research raised shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 13th. Finally, Oppenheimer increased their price target on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th.

Tarsus Pharmaceuticals Stock Down 2.2%

TARS opened at $67.52 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.96 and a quick ratio of 3.17. The business has a 50 day simple moving average of $75.06 and a 200-day simple moving average of $67.83. The stock has a market capitalization of $3.33 billion, a P/E ratio of -4.45 and a beta of 0.34. Tarsus Pharmaceuticals has a 12 month low of $53.89 and a 12 month high of $91.53.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($14.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.46) by ($12.94). Tarsus Pharmaceuticals had a negative net margin of 102.93% and a negative return on equity of 24.51%. The business had revenue of $194.57 million during the quarter, compared to analysts’ expectations of $187.83 million. On average, equities analysts anticipate that Tarsus Pharmaceuticals will post -2.23 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director William Link, PhD sold 12,500 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total transaction of $979,750.00. Following the sale, the director owned 94,487 shares of the company’s stock, valued at approximately $7,405,891.06. The trade was a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak Azamian sold 10,000 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $90.56, for a total transaction of $905,600.00. Following the transaction, the chief executive officer owned 827,991 shares in the company, valued at $74,982,864.96. The trade was a 1.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 48,031 shares of company stock valued at $4,004,227. Corporate insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors have recently modified their holdings of TARS. BlackRock Inc. purchased a new position in Tarsus Pharmaceuticals during the 2nd quarter valued at about $242,705,000. Jupiter Topco LLC acquired a new position in Tarsus Pharmaceuticals during the second quarter worth about $176,834,000. Janus Henderson Group PLC raised its position in Tarsus Pharmaceuticals by 16.1% during the first quarter. Janus Henderson Group PLC now owns 2,240,963 shares of the company’s stock worth $157,223,000 after acquiring an additional 310,638 shares during the last quarter. Bank of America Corp DE raised its position in Tarsus Pharmaceuticals by 57.5% during the first quarter. Bank of America Corp DE now owns 1,194,377 shares of the company’s stock worth $83,786,000 after acquiring an additional 436,271 shares during the last quarter. Finally, TimesSquare Capital Management LLC purchased a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at about $23,249,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals News Roundup

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 63.9% to about $194.5 million, with record sales of XDEMVY. Tarsus expects $715 million–$730 million in XDEMVY sales for 2026, supporting the growth outlook. Article: Tarsus expects $715M-$730M 2026 XDEMVY sales
• Positive Sentiment: Analysts raised price targets and maintained bullish ratings: Guggenheim lifted its target to $97 with a Buy rating, while Oppenheimer raised its target to $103 and kept an Outperform rating. Guggenheim rating Oppenheimer price target
• Neutral Sentiment: Management plans to participate in upcoming investor conferences; this may provide opportunities to discuss the business and outlook, but no new financial information was announced. Tarsus investor conference announcement
• Negative Sentiment: The quarterly net loss widened to $668 million, primarily due to acquisition-related costs, despite revenue growth. Tarsus also deferred European and Japanese filing plans, delaying potential international expansion. Q3 loss and XDEMVY sales Sales outlook and international filing plans

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.